Friday, 14th February 32nd Lorne Cancer 2020

Decode Science Workshop

7:15AM - 8:15AM
Friday, 14th February
Auditorium
Sponsored by:

Accumulation of structural variations (SVs) across the genome is a known trigger factor for oncogenesis. Structural mutations have been clearly implicated in a number of cancers, most notably translocations that result in druggable fusions involving genes such as NTRK, MPRSS2, RET, FGFR3, ALK, and ESR1. Identifying these structural genomic alterations - accurately and comprehensively - is crucial for improving research and ultimately therapies for cancer patients, yet one of primary challenges when solely relied on short read sequencing and chromosomal microarrays

 

Professor Vanessa Hayes, Garvan institute of Medical Research
Dr Yingying Wu, Scientific Affairs Manager, Bionano Genomics

Session 3: Breast & Prostate Cancer

8:30AM - 10:25AM
Friday, 14th February
Auditorium
Chair: Jane Visvader
Sponsored by:

Morning Tea

10:25AM - 10:55AM
Friday, 14th February
Trade Area Level 2&3

Session 4: Tumour Heterogeneity

10:55AM - 1:00PM
Friday, 14th February
Auditorium
Chairs: Alex Swarbrick & Andrew Scott

Lunch

1:00PM - 3:45PM
Friday, 14th February
Trade Area Level 2&3

Meet the Editor

1:00PM - 2:00PM
Friday, 14th February
Auditorium

I-Mei Siu
Senior Editor, Cancer Discovery

BGI International Workshop

2:00PM - 3:00PM
Friday, 14th February
Auditorium
Sponsored by:

Part 1              Precision Oncology: Bringing Omics into Cancer Clinical Practice

Part 2:              Somatic Reference Standards

 

Sharon (Xiaoxia) Song

MGI Tech

Sharon is the Field Application Specialist at MGI Tech Australia, with a commitment to dedicate her knowledge and skills to assist MGI’s local Australian clients. She was previously Microarray Manager of the Australian Translational Genomics Centre.

 

Precision Oncology: Bringing Omics into Cancer Clinical Practice

Over the past few years, the rapid development of innovative sequencing technology has enabled our understanding of cancer to the genetic, molecular and dynamic morphological changes. This technology not only lays the foundation for the emergence of targeted treatment of cancer, but also makes it possible to achieve“Deliver the right prescription to the right patient at the right time”in the clinic. This workshop will focus on the effective application of sequencing technology and integrated analysis of genome, transcriptome, methylation, and single-cell RNA-seq in cancer research. Furthermore, from the scientific findings to improving cancer therapies and clinical care, we will present some of clinical practices in cancer prevention, diagnosis, stratification, treatment and monitoring.

 

Liam McIntyre       

QIMR Berghofer Medical Research Institute

Liam is an organism/disease agnostic bioinformatician with expertise pertaining to NGS, having worked on human germline and somatic diseases, infectious diseases and even the wheat genome. In his current role he has developed a somatic reference standard for pipeline validation and is the technical lead on applying Oxford Nanopore Technologies to paired tumour normal WGS analysis.

 

Somatic Reference Standards

Cancer genomics is paving the way for genomic-guided precision medicine whereby treatments are selected based on a patient’s germline and tumour genomic information. Short paired read whole genome sequencing (WGS) has been the enabling technology to date. The fidelity of WGS analysis can be gauged by a known truth set of variants. The Genome In A Bottle Consortium has generated a powerful germline resource with known variants reported across the genome for a number of publicly‑assessable cell lines. In contrast, the availability of whole genome germline and matched tumour samples with known somatic mutations is lacking. Here, we present two somatic consensus truth sets for the publicly available cell lines COLO829 and HCC1937. For COLO829 – a melanoma cell line – we sequenced 6 technical replicates (Illumina, n=3; BGI, n=3) and matched germline. The breast cancer cell line, HCC1937, was selected to compliment COLO829 due to its high level of structural variation, 4 technical replicates were sequenced (Illumina, n=3; BGI, n=1). Further, one technical replicate of each cell line has been long read sequenced using Oxford Nanopore Technology and the work to date will be discussed.

Session 5: Epigenetics

3:45PM - 5:45PM
Friday, 14th February
Auditorium
Chairs: Marie-Liesse Asselin-Labat & Jason Cain

Dinner at your leisure

5:45PM - 7:45PM
Friday, 14th February

Poster Session II

7:45PM - 10:00PM
Friday, 14th February
Trade Area Level 2&3

Flash Talk Poster

Cep55 loss impedes tumorigenesis in vivo - Behnam Rashidieh